Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novo Bolsters Wegovy Label in Japan with CV Outcome Data
March 6, 2025
- AZ Wins Certification to Allow Use of Pseudonymized Medical Info
March 6, 2025
- DMD Cell Therapy Accepted for FDA Review: Capricor/Nippon Shinyaku
March 6, 2025
- Unexpected Demand Triggers Supply Curb for Eisai’s ALS Med Just 3 Months after Launch; Patients Urge Early Response
March 5, 2025
- Meiji Invests in French Vaccine Player Osivax
March 5, 2025
- Sumitomo Group Continues to Seek Best Partners for Pharma Biz
March 5, 2025
- Protagonist/Takeda’s Hematology Med Makes Mark in PIII
March 5, 2025
- Sato, Eisai to Wind Up Collab on Antifungal Nailin
March 5, 2025
- Nippon Kayaku Files Nuvation-Partnered ROS1 Inhibitor in Japan
March 5, 2025
- Enhertu Hits OS Goal in 2nd-Line Gastric Cancer Use
March 5, 2025
- Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
March 5, 2025
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
- ASKA Ties Up with Philippines’ MedChoice in Thyroid Space
March 4, 2025
- Japan’s 1st CGP Assay for Blood Cancer Now Available: Otsuka
March 4, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Nxera Assigns Cenerimod Rights in Japan, APAC to Viatris
March 3, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…